Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Figure 1 Disposition of patients as of clinical cut-off date January 2008. The intention to treat (ITT) population comprised 77 patients randomized to FOLFOX6 plus cetuximab and 74 randomized to FOLFIRI plus cetuximab. ¹Values based on all treated patients (n = 151). FOLFOX: 5-fluorouracil (5-FU) folinic acid (FA) and oxaliplatin; FOLFIRI: 5-FU FA and irinotecan; PD: Progressive disease; AE: Adverse event.

Figure 2 Kaplan Meier estimates for progression-free survival. A: By treatment group in the ITT population, FOLFOX6 plus cetuximab (n = 77) vs FOLFIRI plus cetuximab (n = 74); B: By KRAS mutation status in the KRAS population, KRAS wild-type (n = 62) vs KRAS mutation (n = 55); C: By tumor KRAS mutation status in patients receiving FOLFOX6 plus cetuximab, KRAS wild-type (n = 34) vs KRAS mutation (n = 23); D: By tumor KRAS mutation status in patients receiving FOLFIRI plus cetuximab, KRAS wild-type (n = 28) vs KRAS mutation (n = 32).

Figure 3 Kaplan Meier estimates for survival. A: By treatment group in the ITT population, FOLFOX6 plus cetuximab (n = 77) vs FOLFIRI plus cetuximab (n = 74); B: By tumor KRAS mutation status, KRAS wild-type (n = 62) vs KRAS mutation (n = 55); C: By KRAS mutation status in patients receiving FOLFOX6 plus cetuximab, KRAS wild-type (n = 34) vs KRAS mutation (n = 23); D: By tumor KRAS mutation status in patients receiving FOLFIRI plus cetuximab, KRAS wild-type (n = 28) vs KRAS mutation (n = 32).